Clermont Université, Université d'Auvergne, UFR Pharmacie, Laboratoire SVFp, 28 Place Henri Dunant, F-63000 Clermont-Ferrand, France.
Vitam Horm. 2012;90:397-417. doi: 10.1016/B978-0-12-398313-8.00015-4.
Obesity is a recognized breast cancer risk factor in postmenopausal women. A recent hypothesis suggests a major role for adipose tissue in carcinogenesis. During many years, the adipose tissue was only considered as a fat storage of energy. This tissue is now described as an endocrine organ secreting a large range of molecules called adipokines. Among these adipokines, adiponectin may play a major role in breast cancer. Plasma adiponectin levels were found to be decreased in cases of breast cancer and in obese patients. Adiponectin may act directly on breast cancer cells by inhibiting proliferation and angiogenesis or by stimulating apoptosis. Increasing adiponectin levels may be of major importance in the prevention and/or the treatment of breast cancer. This therapeutic approach may be of particular significance for obese patients. The beneficial effects of adiponectin and its possible therapeutic applications will be discussed in this review.
肥胖是绝经后妇女乳腺癌的公认危险因素。最近的一个假设表明,脂肪组织在致癌作用中起主要作用。多年来,脂肪组织仅被认为是能量的脂肪储存。现在,这种组织被描述为一种内分泌器官,分泌大量称为脂肪因子的分子。在这些脂肪因子中,脂联素可能在乳腺癌中起主要作用。研究发现,乳腺癌和肥胖患者的血浆脂联素水平降低。脂联素可能通过抑制增殖和血管生成或通过刺激细胞凋亡直接作用于乳腺癌细胞。增加脂联素水平可能对预防和/或治疗乳腺癌具有重要意义。这种治疗方法对于肥胖患者可能具有特别重要的意义。本文将讨论脂联素的有益作用及其可能的治疗应用。